Our results indicate that silencing of KIF3B could suppress breast cancer progression by regulating Wnt/β-catenin signaling and EMT, providing support that KIF3B could serve as a potential therapeutic target for the treatment of breast cancer. This evidence concerns the gene KIF3B and breast carcinoma.